INTRODUCTION {#s1}
============

Classical Hairy cell leukemia (HCL-c) is a rare lymphoid neoplasm with an incidence rate estimated at 0.3 per 100,000 people in United States between 2011 and 2012, and 0.2 per 100,000 people for the variant form of Hairy cell leukemia (HCL-v) \[[@R1]\]. The diagnosis of HCL-c is based on the typical hairy morphology of lymphocytes and the identification of *BRAF^V600E^* mutation \[[@R2]--[@R4]\]. The *BRAF^V600E^* mutation has been described as a driver mutation and detected in the hematopoietic stem cells (HSC) from HCL-c patients \[[@R5]\]. However, additional genetic abnormalities seem to be necessary to induce the disease. Tumor hairy cells display additional genetic alterations that are absent in HSC harboring *BRAF^V600E^*. Whole-exome sequencing (WES) studies have highlighted additional *BRAF^V600E^* single nucleotide variants (SNV) \[[@R4], [@R6]--[@R8]\]. Some of these SNVs are probably passenger mutations, but others, because of their recurrence, appear to be more relevant to the disease.

The *BRAF^V600E^* mutation is absent in some HCL-c patients \[[@R9], [@R10]\]. In these cases, the distinction between HCL-c and the variant form of hairy cell leukemia (HCL-v) or splenic diffuse red pulp lymphoma (SRDPL) can be complex. In HCL-c patients, the absence of *BRAF^V600E^* has been associated with an unmutated immunoglobulin heavy chain variable (IGHV) gene, the preferential use of the VH4-34 gene (7--11% of cases), mutations targeting *MAP2K1* (6/7 cases) and a poor prognosis \[[@R6], [@R10], [@R11]\]. HCL-v was introduced as provisional entity in the WHO classification of tumors in 2008 and 2016 \[[@R2], [@R3]\]. There are common characteristics between HCL-c and HCL-v, such as circulating villous lymphocytes and a histologic infiltration of the spleen with the involvement of the red pulp and atrophy of the white pulp \[[@R12]\]. The essential difference between the two diseases is the five-year overall survival rate: 78--92% for HCL-c and 57% for HCL-v \[[@R1], [@R13]\]. HCL-v diagnosis is essential because guidelines of care-management between HCL-c and HCL-v are different \[[@R14], [@R15]\]. The distinction between HCL-c and HCL-v is based on cytology with the presence of constant prominent nucleoli in HCL-v cells, as well as the immunophenotype. Classical hairy cells co-express CD103, CD123, CD25 and CD11c with an HCL score (one point given for each positive markers) ≥3 in 98% of cases \[[@R16]\]. The variant form lacks CD25 and has an HCL score \<3. SDRPL, classified as a provisional entity by the WHO in 2008 and 2016, is a splenic hairy cell proliferation that is similar to HCL but quite distinct from splenic marginal zone lymphoma (SMZL) \[[@R17]--[@R19]\]. The distinction between HCL-v and SDRPL can be challenging because of an overlap in pathologies of the two cancers.

The next generation sequencing (NGS) approach and the sequencing of targeted genes have already proven to be useful for the diagnosis, classification and prognosis of lymphoid neoplasms \[[@R20]\]. Therefore, in the aim to develop a genomic diagnostic tool to distinguish these entities, we designed a panel of relevant target genes for HCL based on a literature review of WES studies \[[@R4], [@R6]--[@R8]\] and analyzed retrospectively HCL-c and HCL-v well-defined cases.

RESULTS {#s2}
=======

Single nucleotide variants (SNVs) featured in diagnosis samples {#s2_1}
---------------------------------------------------------------

The Trichopanel was relevant for 96% (23/24) of patients. No SNVs were found in one patient (UPN-10) for any of the 21 targeted genes. The Trichopanel library sequencing yielded a median overall depth per sample of 322X \[89X-533X\] with 97.25% of targeted bases covered by 20 or more reads ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). For the samples obtained at diagnosis, a total of 891 variants (median per sample 37.5 \[[@R6]--[@R52]\]) were detected, then filtered on quality. Synonymous variations, intronic variations, and small nucleotide polymorphism (SNP) were excluded. Functional relevance was analyzed *in silico* using three validated algorithms (SIFT^®^, CADD^®^ and polyphen2^®^) ([Supplementary Table 5](#SD4){ref-type="supplementary-material"}). After screening, 35 non-synonymous SNVs were validated with a range of 0--3 variants per samples (Figure [1](#F1){ref-type="fig"} and [Supplementary Table 5](#SD4){ref-type="supplementary-material"}). Finally, the Trichopanel identified relevant mutations in *BRAF* (*n* = 18), *KLF2* (*n* = 4), *MAP2K1* (*n* = 3), *KDM6A* (*n* = 2), *CDKN1B* (*n* = 2), *ARID1A* (*n* = 2), *CREBBP* (*n* = 2), *NOTCH1* (*n* = 1) and ARID1B (*n* = 1) (Figure [1](#F1){ref-type="fig"}).

![Heat-map representation of mutations and CNV distribution in HCL-c and HCL-v\
Each column represents one patient (UPN), and each row is one gene of the Trichopanel. The intensity of color is proportional to the rVAF (dark blue, rVAF value close to 1; light blue, rVAF value \< 0.3). Gray represents relapse/evolution samples. Mutations and rVAF details are provided in the [Supplementary Table 4](#SD3){ref-type="supplementary-material"}. The gene copy number variation was reported for the relevant gene *MAPK15,* CN not done in gray. Abbreviations: CN, copy number; HCL-c, hairy cell leukemia classic form; HCL-v, variant form. ^\*^ Relapse/evolution samples.](oncotarget-09-28866-g001){#F1}

Cell lines and patient characteristics {#s2_2}
--------------------------------------

The Trichopanel was validated by the sequencing of three cell lines (BONNA-12, JOK-1 and JVM-3). In agreement with previously published data, we found no *BRAF^V600E^* mutations in these cell lines, but other mutations were found (e.g., *NOTCH1^T2466M^* in BONNA-12, *BRAF^K601N^* in JVM-3 \[[@R21]\]) (COSMIC Cell lines project <http://cancer.sanger.ac.uk/cell_lines>). In addition, several new SNVs were found: *TP53^Y234H^*/*TP53^R213Q^* in JOK-1 and *ARID1B^P1435L^* in JVM-3. (Figure [1](#F1){ref-type="fig"}, [Supplementary Table 4](#SD3){ref-type="supplementary-material"}).

Patient characteristics of our cohort are summarized in Table [1](#T1){ref-type="table"} and in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}. In total, 24 patients were analyzed (20 HCL-c and four HCL-v), and all patients provided samples at the time of diagnosis. For 5 patients, samples taken at the time of diagnosis and relapse/follow-up were investigated. In HCL-c patients, 88.2% (15/17) were treated with the first-line drug cladribine (*n* = 12), interferon a (*n* = 2) or pentostatine (*n* = 1). Forty percent (6/15) of those patients progressed with a median of 25 months \[0--166.5\]. Of the two untreated patients, one had no treatment criteria (UPN-19, 38.5 months of follow up), and the other (UPN-17) died on the day of the diagnosis.

###### Patient characteristics of the cohort

  *n* = patients                               HCL-c (*n* = 20)      HCL-v (*n* = 4)       TOTAL (*n* = 24)
  -------------------------------------------- --------------------- --------------------- ---------------------
  Diagnosis samples                            20                    4                     24
  Relapse/Evolution samples                    2                     3                     5
  Diagnosis age (years) (Median \[min-max\])   54.5 \[42--92\]       69.5 \[64--82\]       60.5 \[42--92\]
  Sex Ratio Male/Female                        15/5                  4/0                   19/5
  Folow up (month) (Median \[min-max\])        37.1 \[0.0--218.5\]   19.9 \[8.9--31.4\]    32.3 \[0.0--218.5\]
  Neutropenia (%, *n*)                         82.3% (14/17)         0% (0/4)              66.7% (14/21)
  Monocytopenia (%, *n*)                       87.5% (14/16)         0% (0/4)              70% (14/20)
  Anemia (%, *n*)                              47% (8/17)            75% (3/4)             52.4% (11/21)
  Treatment (%, *n*)                           88.2% (15/17)         50% (2/4)             82.8% (18/22)
  TFS (month) (Median \[min-max\])             1.4 \[0.0--30.0\]     6.05 \[2.0--19.87\]   1.7 \[0.0--30.0\]
  Relapses (%, *n*)                            40.0% (6/15)          50% (2/4)             44.4% (8/18)
  PFS (month) (Median \[min-max\])             25.0 \[0.0--166.5\]   15.1 \[4.1--26.0\]    25.0 \[0.0--166.5\]

Definitions: Neutropenia: absolute polynuclear cells count (PNN) \<1.5 × 10^9^/L; Monocytopenia: absolute monocytes count \<0.20 × 10^9^/L; Anemia: hemoglobinemia rate \<120 g/L (female) \<130 g/L (male).

Abbreviations: PFS: Progression Free Survival, TFS: Treatment Free Suvival.

Of the HCL-v patients, two (UPN-v1 and UPN-v2) were treated with Rituximab plus cladribine or cladribine alone; they progressed rapidly at 4.1 and 26 months respectively. The remaining HLC-v patients (UPN-v3 and UPN-v4) were untreated because of palliative care and the absence of treatment criteria, respectively (follow up of 8.5 months).

HCL-c patients at diagnosis have recurrent gene mutations {#s2_3}
---------------------------------------------------------

The *BRAF^V600E^* mutation was found in 90% (18/20) of HCL-c patients. For the two patients without the *BRAF^V600E^* mutation, one (UPN-40) had a mutation in *MAP2K1,* and the other (UPN-10) had no alternative mutations in any of the targeted genes. The frequency of the *BRAF^V600E^* allele was compatible with heterozygosity, with a median rVAF of 0.48 ± 0.12 (Figure [1](#F1){ref-type="fig"} and [Supplementary Table 5](#SD4){ref-type="supplementary-material"}). In addition to *BRAF^V600E^*, mutations in *KLF2* (*n* = 3), *CDKN1B* (*n* = 2), *NOTCH1* (*n* = 1), ARID1B (*n* = 1) and CREBBP (*n* = 1) were found in 33% (6/18) of cases. *KLF2* missense mutations found in three patients were localized in two specific domains, the zinc finger domain and the nuclear localization signal (Figure [2](#F2){ref-type="fig"}). *CDKN1B* mutations were found in two patients; these mutations were stop-gain and stop-loss mutations. One mutation had a rVAF compatible with heterozygosity (UPN-2; rVAF = 0.58), and the other was consistent with a sub-clonal mutation (UPN-25; rVAF = 0.09) ([Supplementary Table 5](#SD4){ref-type="supplementary-material"}).

![Localization of the *KLF2*, *MAP2K1* and *KDM6A* mutations in the corresponding proteins\
Distribution of mutations along the KLF2, MAP2K1 and KDM6A proteins. The exons targeted by the Trichopanel are represented in gray. Mutations are indicated as follows: green circles, missense mutations; blue circles, non-sense mutations; orange circles, deletions; green diamond, splicing variant. The SNVs previously described in HCL \[[@R8]\] or SMZL \[[@R25], [@R26]\] are in violet. Abbreviations: Helical domain (H), Jumonji domain (JmJC), nuclear export signal (NES), nuclear localization signal (NLS), negative regulatory region (NNR), Prolin-rich domain (Pro-rich), tetratricopeptids repeats (TTR), Zinc binding domain(Zn), Zinc fingers domain (ZnF).](oncotarget-09-28866-g002){#F2}

Epigenetic mutations are recurrent in HCL-v patients {#s2_4}
----------------------------------------------------

The *MAP2K1^I103N^* and *MAP2K1^Q56P^* mutations were found in two of four HCL-v patients (UPN-v1 and UPN-v3, respectively). All HCL-v patients had SNVs in epigenetic regulatory genes including *KDM6A* (*n* = 2), *CREBBP* (*n* = 1) and *ARID1A* (*n* = 1) (Figure [1](#F1){ref-type="fig"} and [Supplementary Table 5](#SD4){ref-type="supplementary-material"}). The two *KDM6A* mutations were potentially deleterious (UPN-v1 and UPN-v2). One was a frameshift deletion, and the other was a splicing variant leading to a loss of exon 24 as confirmed by RNA sequencing (Figure [2](#F2){ref-type="fig"} and [Supplementary Figure 1B](#SD1){ref-type="supplementary-material"}). The calculated rVAF were 1.01 and 0.99, respectively, in these two male patients, in agreement with the location of *KDM6A* in the X chromosome.

Sub-clonal mutations and variant allele frequency changes are found at the disease relapse {#s2_5}
------------------------------------------------------------------------------------------

We analyzed serial samples from five patients (two HCL-c and three HCL-v) at diagnosis and relapse (Figure [3](#F3){ref-type="fig"}). For one HCL-c patient (UPN-6), we observed the same mutational pattern in the two samples. In the second case (UPN-40), two new sub-clonal mutations (*BCOR^E1430X^* and *XPO1^E571K^*) were characterized. In the three HCL-v patients (two treated and one untreated), no new mutations were observed but variations of the rVAF were identified in two cases. UPN-v1 had an increased allele frequency of *MAP2K1^I103N^* (rVAF = 0.07 at diagnosis and 0.41 at relapse). UPN-v3 had a decreased allele frequency of the *CREBBP* splicing variant (rVAF = 0.34 to 0.06). This patient was left untreated between the first and the second samples.

![The mutations described at diagnosis are either maintained or evolving at relapse\
Representation of the relevant HCL-c (UPN-40) and HCL-v patients (UPNv1 and UPN-v3) tested at diagnosis and at relapse. For each patient, color-coded circles estimate the rVAF of the indicated mutations. Relevant times points and treatment are indicated by arrows. Abbreviations: CEP Cisplatin-Endoxan-Epirubicin, R-Cladribine: Rituximab + cladribine.](oncotarget-09-28866-g003){#F3}

*MAPK15* gene loss is the most frequent abnormality of CNVs {#s2_6}
-----------------------------------------------------------

CNV analysis highlighted various abnormalities: the most frequent CNV was a loss of one copy of *MAPK15* found in 37.5% of patients (9/24) (Figure [1](#F1){ref-type="fig"}). According to the *MAPK15* CNV status, there were no significant differences for TFS and OS in HCL-c patients, but PFS was significantly better in HCL-c patients with a *MAPK15* deletion (Figure [4](#F4){ref-type="fig"}). Four patients had a loss of *EZH2* gene copy (UPN-18, UPN-40, UPN-v1 and UPN-v2). On the basis of their karyotypes, two of them had an abnormal chromosome 7q (one deletion and one rearrangement) involving the loss of *BRAF* (7q34) ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}).

![*MAPK15* deletion improves the progression-free survival in HCL-c patients\
Kaplan-Meier representation of Treatment-free survival (TFS), Progression-free survival (PFS) and Overall survival (OS) of HCL-c according to *MAPK15* copy loss status. *p*-values were calculated with Log-rank Test. In the "*MAPK15* normal" group, patients were given first-line treatment with Interferon *n* = 1, pentostatine *n* = 2 or cladribine *n* = 5. In the "*MAPK15* loss" group, patients were given first-line treatment with Interferon *n* = 1 or cladribine *n* = 6. *MAPK15* loss is associated with significantly improved PFS in HLC-c patients, and no significant differences were observed in TFS and OS.](oncotarget-09-28866-g004){#F4}

DISCUSSION {#s3}
==========

HCL cell lines are atypical. As expected, none had the *BRAF^V600E^* mutation \[[@R23]\], suggesting that a hairy cell phenotype-like can be observed without this driver mutation. In contrast, other mutations were found in *TP53*, *NOTCH1*, *ARID1B* and *BRAF* with an allele frequency compatible with their complex karyotype ([Supplementary Table 4](#SD3){ref-type="supplementary-material"}). JVM-3 is a B prolymphocytic leukemia-derived cell line and harbors *BRAF^K601N^* \[[@R22]\]. This mutation is found in rare cases of melanoma and leads to MAPK pathway activation \[[@R24]\]. Altogether, the cell line data show that JVM-3 could be a model for studying HCL.

Consistent with the literature, *BRAF^V600E^* mutations were found in 90% (18/20) of HCL-c patients \[[@R4], [@R10]\]. The proportion of HCL-c patients with *BRAF^WT^* differs according to the studies, ranging from 0 to 20% \[[@R4], [@R10]\]. Some alternative *BRAF^V600E^* mutations were found in exon 11 \[[@R9]\]. In this study, the two HCL-c patients with *BRAF*^WT^ had no alternative BRAF mutations in exons 11 or 15. For these patients, the diagnosis of the classical form was confirmed by immunophenotyping, the HCL score (4/4), and the hairy cell morphology without prominent nucleoli. These criteria indicate that *BRAF^V600E^* is not the unique driver mutation in all HCL-c cases. IGHV-4-34 gene rearrangements are associated with *BRAF^WT^* in HCL-c patients \[[@R10]\]. In this study, IGHV status was not examined.

One third of the HCL-c patients had mutations in addition to *BRAF* mutations (one to two additional altered genes per patient). In all patients with these additional mutations (6/6), rVAFs were close to 0.50 (0.47 ± 0.16), confirming the early-onset of the mutation and the hypothesis in which mutations in addition to *BRAF* are necessary to the disease \[[@R5]\]. Two HCL-c patients with *BRAF^V600E^* (UPN-25 and UPN-38) had additional sub-clonal mutations in *CDKN1B^W76X^* (rVAF = 0.09) and *KLF2^T284S^* (rVAF = 0.16), respectively. The characterization of these sub-clonal mutations could be necessary for the management of future treatment and to avoid the promotion of a sub-clone during the relapse.

The Trichopanel detected *KLF2* mutations in 15% (3/20) of HCL-c patients. This percentage is comparable with those reported in the literature, reported in 10--16% of cases \[[@R25], [@R26]\]. *KLF2*, involved in three patients, plays a key role in B-cell homing to lymph nodes and inhibition of the NF-κB pathway^26,27^. *KLF2^275N^*, *KLF2^275T^* and *KFL2^T271I^* mutations found in those patients are localized within the zinc finger domain or the nuclear localization signal (NLS). These mutations have been described in splenic zone marginal lymphoma (SMZL) as possibly deleterious mutations \[[@R25], [@R26]\]. Moreover, mutations involving the NLS lead to cytoplasmic relocalization of KFL2 and affect transcription factor activity \[[@R26]\]. In a murine model, KLF2 gene knock-out is not sufficient to induce lymphoma but results in deregulation of B-cell differentiation and trafficking \[[@R27], [@R28]\]. Thus, mutations in *KLF2* in HCL-c patients could explain both the extra-nodal localization of hairy cells and NF-κB pathway upregulation \[[@R29]\]. One patient (UPN-38) had two mutations in KLF2: *KFL2^T271I^* (rVAF = 0.42) and *KLF2^T284S^* (rVAF = 0.16). Multiple KLF2 mutations (2--5) have been described previously in eleven patients with HLC-c (*n* = 1), extra-nodal marginal zone lymphoma (=1), Burkitt lymphoma (*n* = 1), SMZL (*n* = 1) and diffuse large B cell lymphoma (*n* = 7), and in most cases, the *KLF2* mutations were located on separated alleles \[[@R26]\]. The effects of *KLF2* mutations on HCL are still unclear and further studies are necessary.

Alterations of cell cycle and apoptosis are common in hematologic neoplasms. In this study, two HCL-c patients had *CDKN1B* mutations (2/20, 10%), and none had *TP53* mutations. These data are consistent with previously published data in which *CDKN1B* mutations are found in 11--16% of HCL-c patients \[[@R7], [@R30]\]. In HCL-c patients, the frequency of *TP53* mutations differs considerably from one study to another, ranging from 0--2% \[[@R30], [@R31]\] to 27% \[[@R32]\]. In our study, patients with *CDKN1B^W76X^* and *CDKN1B^X199S^* mutations had an atypical HCL immunophenotype with the expression of CD10. CD10 expression in HCL is rare (10--20% of cases) \[[@R33]\]. Currently, no studies have reported a correlation between *CDKN1B* mutation and CD10 expression.

In three of the six patients with *BRAF^WT^* (2 HCL-c and 4 HCL-v), we found mutations in *MAP2K1*. This finding is consistent with previously published data in which 48% of HCL (classical and variant form) patients with *BRAF^WT^* had MAP2K1 mutations \[[@R6]\]. More precisely, *MAP2K1* activating mutations are found in 86% (6/7) of *BRAF^WT^-*containing HCL-c patients and 42% (10/24) of HCL-v patients \[[@R6]\]. *BRAF* and *MAP2K1* mutations are mutually exclusive in HCL \[[@R6]\]. The mutations *MAP2K1^Q56P^* and *MAP2K1^K57N^* (UPN-v3 and UPN-40, respectively) that we found are close to the negative regulatory domain of the protein and lead to ERK phosphorylation \[[@R34], [@R35]\]. Interestingly, although the presence of *MAP2K1^K57N^* would improve of the sensitivity of cells to MEK inhibitors, *MAP2K1^Q56P^* could generate resistance \[[@R35], [@R36]\]. *MAP2K1^I103N^* (in UPN-v1) is localized close to the C-terminal helix of the protein \[[@R34]\]. Currently, this mutation is not described as an MEK activator but could confer resistance to MEK inhibitors by impairing the allosteric binding of the drug \[[@R35]\]. In the UPN-v1 patient, the *MAP2K1^I103N^* mutation was sub-clonal at the initial diagnosis (rVAF = 0.07) and considerably increased at the time of relapse (rVAF = 0.41). Altogether, these data showed that *MAP2K1^I103N^* would not confer a proliferative or survival advantage at time of diagnosis but could induce a bad-responder phenotype, even in the absence of MEK inhibitor. Indeed, UPN-v1 was treated with cladribine-rituximab and then moxetumomab-pasudotox as a second line of treatment. The detection of these mutations seems essential in the future clinical management of HCL patients.

No *TP53* mutations were found in HCL-v patients, even at relapse. *TP53* mutations have been described in nearly 30% of HCL-v cases \[[@R13], [@R31]\].

Finally, we described new *KDM6A* mutations in HCL-v patients. Both patients were hemizygous for the mutations as *KDM6A* is located on chromosome X. The presence of tumor suppressor genes on the chromosome X has been used to explain the imbalanced male/female sex ratio in cancers \[[@R37]\]. Moreover, HCL is known to have a 5:1 male/female sex ratio \[[@R3]\]. *KDM6A* (also known as Ubiquitously Transcribed Tetratricopeptide Repeat Protein X-Linked (UTX)) encodes a lysine demethylase protein that removes di- and tri-methyl groups from lysine 27 of Histone 3 (H3K27). Disruptive *KDM6A* mutations have been found in multiple myeloma, bladder neoplasms and T cell acute lymphoblastic leukemia (T-ALL) \[[@R38]\]*. KDM6A* mutations leading to a loss of function were previously described in 3 HCL-c patients \[[@R6], [@R7], [@R39]\]. Two were atypical patients, and one had a stop-gain mutation in *KDM6A* found in the relapse sample, possibly due to vemurafenib treatment \[[@R7]\]. Another patient had the *BRAF*^WT^ allele with an unmutated immunoglobulin heavy gene VH4-34 \[[@R6]\]. This sub-type of HCL is considered to be bad responder to classical drug therapies \[[@R31]\]. A disruptive *KDM6A* mutation was also recently found in one SDRPL patient and in one HCL-v patient \[[@R30], [@R39]\]. In our series, one patient with a *KDM6A* mutation was non-responsive to first and second line therapies.

Those mutations and the two mutations found in our series result in the loss of the highly conserved C-terminal region of KDM6A (including Jumomji and zinc binding domains) which is essential for its demethylase activity \[[@R40]\]. Loss of KDM6A activity may sensitize tumor cells to demethylating agents such as EZH2 inhibitors \[[@R41]\]. Indeed, KDM6A inactivation (*KDM6A^R1279X^*) in T-ALL cell lines showed an improvement in the sensitivity to DZNEP, an epigenetic compound that targets methylation of H3K27 \[[@R42]\].

As already described in chronic lymphocytic leukemia \[[@R43]\], the analysis of diagnosis/relapse samples highlighted the heterogeneity of tumor cells and their sub-clonal evolution during the course of the disease. *BCOR* was recently described as a new recurrent gene altered in SDRPL. Mutations were found in 6/42 SRDPL and loss of *BCOR* expression in 4 other cases \[[@R39]\]. In our series, a *BCOR* mutation (*BCOR^E1430X^*) was found at the relapse of patient UPN-40 as a sub-clonal stop-gain mutation (rVAF = 0.15).

*XPO1* encodes for exportin 1, a protein that plays a key role in the nuclear export of tumor suppressors such as p53, p27 and Iκ-B, an inhibitor of the NF-κB pathway \[[@R44]\]. A hotspot *XPO1^E571K^* mutation has been found in primary mediastinal B-cell lymphoma, classical Hodgkin lymphoma (HL-c) and chronic lymphocytic leukemia (CLL) \[[@R45]--[@R47]\]. One patient (UPN-40) presented the *XPO1^E571K^* hotspot mutation at relapse. The significance of the presence of a sub-clonal *XPO1^E571K^* mutation at relapse is unknown.

The *MAPK15* gene encodes extracellular regulated kinase 8 (ERK8), a recently identified member of the MAPK family. This gene is located in chromosome 8. Its activity is still unclear, but it appears to play an oncogenic role. ERK8 stabilizes c-JUN and regulates autophagy and cell transformation \[[@R48], [@R49]\]. Overexpression of *MAPK15* was described in solid neoplasms \[[@R49], [@R50]\]. Thanks to this effect on MAPK pathway, *MAPK15* loss could potentially antagonize the constitutive activation of MAPK pathway in *BRAF^V600E^* hairy cells. Further investigations of the link between *BRAF^V600E^* and *MAPK15* are necessary. Here, we found that loss of *MAPK15* copy number improved PFS in HCL-c patients without repercussion on OS (Figure [4](#F4){ref-type="fig"}).

MATERIALS AND METHODS {#s4}
=====================

Patients and patient samples {#s4_1}
----------------------------

We studied three cell lines (BONNA-12, JOK-1, JVM3 (obtained from German Collection of Microorganisms and Cell Culture or offered by Toulouse University Hospital) 20 HCL-c and 4 HCL-v patients from an initial diagnosis and 2 HCL-c and 3 HCL-v patients with relapsing disease. Mononuclear cells were obtained from peripheral blood (17 samples), bone marrow aspirates (10 samples) or 2 biopsy specimens (spleen and nodule). The HCL-c disease was diagnosed in accordance with the WHO 2016 classification \[[@R3]\] by combination of clinical criteria, cytology, presence of *BRAF^V600E^* and immunophenotyping. The HCL-v disease was diagnosed by clinical criteria, hairy cell morphology with constant prominent nucleoli, the absence of *BRAF^V600E^*, and immunophenotyping ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). Informed consent was obtained from patients, and the procedures were conducted in accordance with the Helsinki Declaration and the policy of the CHU de Caen.

Next generation sequencing {#s4_2}
--------------------------

The PBMC fraction was collected after gradient density separation (histopaque^®^). DNA was extracted with the automated device MagnaPur^®^ (Roche Lifescience) according to the manufacturer\'s recommendations. Library design was performed with the Ion Ampliseq Designer™ software. The DNA library (Ion Ampliseq™ Library kit), template preparation/chip loading (Ion Chef™ system + Ion PGM™ Hi-Q Chef Kit Reagent) and sequencing (Ion Torrent PGM™) were performed according to the manufacturer\'s recommendations (ThermoFisher Scientific). The Trichopanel design covers 71,020 bases using 712 amplicons ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). The analyzed genes belong to nine functional groups: MAPK signaling pathway (*BRAF*, *MAP2K1*, *DUSP2*, *MAPK15*), epigenetic regulation (*ARID1A*, *ARID1B*, *EZH2*, *KDM6A*, *CREBBP*), cell cycle/apoptosis (*TP53*, *CDKN1B*, *XPO1*), homing (*KLF2*, *CXCR4*), NOTCH pathway (*NOTCH1*, *NOTCH2*), NF-κB pathway (*MYD88*), inflammation (*ANXA1*), splicing (*U2AF1*), differentiation (*BCOR*) and extracellular transport (*ABCA8*), according to published WES data \[[@R4], [@R6]--[@R8]\]. Data analysis was performed with Torrent suite^TM^ software, and then, variant analysis was performed using an in-house generated bioinformatic pipeline (Generate reports^®^) as previously described \[[@R20]\]. The ratio of variant allele frequency (VAF), rVAF, was calculated as the percentage of VAF on divided by the percentage of tumor infiltration. Splicing prediction was performed using an in-house generated bioinformatic pipeline (Alamut^®^ Visual 2.9 interactive Biosoftware) as previously described \[[@R51]\] ([Supplementary Figure 1A](#SD1){ref-type="supplementary-material"}). Functional relevance was analyzed *in silico* using three validated algorithms (SIFT^®^, CADD^®^ and polyphen2^®^).

Copy number variation (CNV) analysis of the regions sequenced by the Trichopanel was performed as previously described \[[@R52]\], and patients\' data were normalized to DNA samples from eight healthy patients.

Sanger sequencing {#s4_3}
-----------------

Primer sequences for PCR amplification were designed with the Primer3 software (v4.0.0, <http://primer3.ut.ee>) ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). Sequencing was performed on an ABI Prism31000 device (ThermoFisher Scientific) according to the manufacturer\'s recommendations.

Immunophenotyping {#s4_4}
-----------------

Multiparameter flow cytometric immunophenotyping was performed on a FACS CANTO II or a FACSCalibur (Becton Dickinson, (BD)), and the data were used to characterize hairy cells (HC) and to quantify tumor infiltration (See Supplementary Methods).

Statistical analysis {#s4_5}
--------------------

Statistical representations of the Kaplan--Meir test on Treatment Free Survival (TFS), Progression Free Survival (PFS) and Overall Survival (OS) were performed using GraphPad Prism version 7.00, and *p*-values were calculated with Log-rank Test. TFS was calculated from the date of diagnosis to date of first treatment or last patient follow-up. OS was calculated from the date of diagnosis to date of death or last patient follow-up. PFS was calculated from the date of diagnosis until disease progression, relapse, death or last patient follow-up. *p* values \< 0.05 were considered statistically significant.

CONCLUSIONS {#s5}
===========

The use of the Trichopanel has a potential benefit in the diagnosis and the prognosis of HCL-c and HCL-v patients, who need to be confirmed in a larger cohort. This is a relatively easy tool for routine analysis. The *KDM6A* loss of function mutation described in this study needs to be further investigated in order to determine the role of demethylating agents in those patients.
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CNV

:   copy number variation

HCL-c

:   classical hairy cell leukemia

HCL-v

:   hairy cell leukemia-variant

SDRPL

:   splenic diffuse red pulp lymphoma

SMZL

:   splenic marginal zone lymphoma

SNV

:   single nucleotide variation
